Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib.

Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib. Neoplasma. 2020 Jul 14;: Authors: Cheng Y, Du FC, Fang FQ, Duan ZJ, Wei L, Shi KG Abstract The clinical efficiency and adverse reactions of anlotinib in metastatic colorectal cancer (mCRC) as a third-line treatment compared with chemotherapy and regorafenib or fruquintinib was explored in this study. Clinical data from 105 mCRC patients who failed at least two lines of chemotherapy were collected. The patients were divided into three groups based on their third-line therapeutic regimen: third-line chemotherapy only (group A); anlotinib (group B); and fruquintinib or regorafenib (group C). The result showed that the ORR and DCR of group B (14.29%, 85.71%) were higher than those of group A (0%, 40.00%). The ORRs of group B and group C were 14.29% and 20.00%, respectively. Group B and group C had the same DCR, 85.71%. The mean PFS values of group B (3.46 months) and group C (3.33 months) were longer than that of group A (2.25 months) (χ2 = 84.255, P < 0.001) and the mean PFS values of group B and group C were similar (χ2 = 0.884, P = 0.347). The mean OS of group B was 9.22 months, which was longer than that of group A (6.95 months) (χ2 = 38.837, P < 0.001). The mean OS values of group B (9.22 months) and group C (9.38 months) were not significantly different (χ2 = 0.456, P = 0.499). The incid...
Source: Neoplasma - Category: Cancer & Oncology Authors: Tags: Neoplasma Source Type: research